Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
Phase 3
210
about 8 years
1–11
19 sites in CA, CO, GA +12
About this study
This trial is testing a treatment called VX-121/TEZ/D-IVA for children with cystic fibrosis who have at least one mutation that responds to triple combination therapy. The goal is to see if this treatment is safe, well-tolerated, and effective in these individuals.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take VX-121/TEZ/D-IVA
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Secondary: Part B: Absolute Change in BMI-for-age Z-score, Part B: Absolute Change in Body Mass Index (BMI), Part B: Absolute Change in Weight, Part B: Absolute Change in Weight-for-age Z-score, Part B: Absolute Change in Weight-for-length, Part B: Absolute Change in Weight-for-length Z-score
Respiratory